• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Merrimack Pharmaceuticals Inc.

    3/22/24 9:46:00 AM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MACK alert in real time by email
    DEFA14A 1 d780936ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.)

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    MERRIMACK PHARMACEUTICALS, INC.

     

     

    (Name of Registrant as Specified in its Charter)

     

    Not applicable.

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


     

    LOGO

      LOGO
     

    Online

     

    Go to www.envisionreports.com/MACK-SM or scan the QR code – login details are located in the shaded bar below.

     

       
     Special Meeting of Stockholders Notice   LOGO     

    Important Notice Regarding the Availability of Proxy Materials for the

    Merrimack Pharmaceuticals, Inc. Special Meeting of Stockholders to be Held on May 10, 2024.

    Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the Special Meeting of Stockholders are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the Special Meeting of Stockholders are on the reverse side. Your vote is important!

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2024 Proxy Statement and the 2023 Special Report on Form 10-K to stockholders are available at:

     

    LOGO

     

     

    LOGO

       Easy Online Access – View your proxy materials and vote.
      

     

    Step 1:  Go to www.envisionreports.com/MACK-SM.

       Step 2:  Click on Cast Your Vote or Request Materials.
       Step 3:  Follow the instructions on the screen to log in.
       Step 4:  Make your selections as instructed on each screen for your delivery preferences.
       Step 5:  Vote your shares.

    When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.

     

     

     

    LOGO    Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before April 30, 2024 to facilitate timely delivery.

     

    LOGO

    03YIBC


     

     

     Special Meeting of Stockholders Notice

     

        

    The Special Meeting of Stockholders of Merrimack Pharmaceuticals, Inc. will be held on Friday, May 10, 2024 at 10:00 a.m. Eastern Time, virtually via the internet at meetnow.global/MX9GMCA. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form.

    Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.

    The Board of Directors recommend a vote FOR Proposals 1 and 2:

      1.

    To approve the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the “Plan of Dissolution”), which, if approved, will authorize the Company and the Board of Directors to liquidate and dissolve the Company (the “Dissolution”) in accordance with the Plan of Dissolution (the “Dissolution Proposal”); and

      2.

    To approve one or more adjournments of the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Dissolution Proposal or in the absence of a quorum.

    PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card.

     

     

     

     

      LOGO     Here’s how to order a copy of the proxy materials and select delivery preferences:
     

     

    Current and future delivery requests can be submitted using the options below.

     

    If you request an email copy, you will receive an email with a link to the current meeting materials.

     

     

    PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

     

    _   

     

      Internet – Go to www.envisionreports.com/MACK-SM. Click Cast Your Vote or Request Materials.
     

    _   

     

      Phone – Call us free of charge at 1-866-641-4276.
     

    _   

     

     

     

    Email – Send an email to [email protected] with “Proxy Materials Merrimack Pharmaceuticals, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

       

     

    To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by April 30, 2024.

    Get the next $MACK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MACK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andersen Eric bought $651,754 worth of shares (49,550 units at $13.15) (SEC Form 4)

    4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

    12/28/23 4:05:12 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Andersen Eric bought $1,298,472 worth of shares (101,050 units at $12.85) (SEC Form 4)

    4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

    12/11/23 4:05:08 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Andersen Eric bought $3,750 worth of shares (300 units at $12.50) (SEC Form 4)

    4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

    11/20/23 6:59:37 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andersen Eric bought $651,754 worth of shares (49,550 units at $13.15) (SEC Form 4)

    4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

    12/28/23 4:05:12 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Andersen Eric bought $1,298,472 worth of shares (101,050 units at $12.85) (SEC Form 4)

    4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

    12/11/23 4:05:08 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Andersen Eric bought $3,750 worth of shares (300 units at $12.50) (SEC Form 4)

    4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)

    11/20/23 6:59:37 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MACK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    5/14/24 2:20:00 AM ET
    $KRON
    $MACK
    $MXCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments

    Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

    Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr

    5/10/24 4:30:00 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

    Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua

    5/9/24 7:30:00 AM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MACK
    SEC Filings

    View All

    SEC Form 15-12G filed by Merrimack Pharmaceuticals Inc.

    15-12G - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

    5/20/24 4:05:28 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Merrimack Pharmaceuticals Inc.

    10-Q - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

    5/15/24 4:15:28 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25 filed by Merrimack Pharmaceuticals Inc.

    25 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)

    5/10/24 4:45:35 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MACK
    Financials

    Live finance-specific insights

    View All

    Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

    Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr

    5/10/24 4:30:00 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

    Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua

    5/9/24 7:30:00 AM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

    Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024. Under the Plan of Dissolution, Merrimack intends to issue an initial liquidating cash dividend to its stockholders, subject to receipt of stockholder approval of the Plan of Dissolution. The Company currently estimates a cash divid

    4/30/24 5:15:00 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

    SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

    2/14/24 4:20:24 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

    SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

    1/25/24 4:05:32 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)

    SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)

    12/13/23 4:05:25 PM ET
    $MACK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MACK
    Leadership Updates

    Live Leadership Updates

    View All

    Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    5/14/24 2:20:00 AM ET
    $KRON
    $MACK
    $MXCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments

    180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

    MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors ("Board") effective June 15, 2021. Russell Ray was formerly Managing Director and Co-Head of Global Health Care at Credit Suisse First Boston Corporation where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco focused on providing corporate finance and M&A adv

    5/28/21 8:00:00 AM ET
    $MACK
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care